Aliqopa Approval History
FDA Approved: Yes (First approved September 14, 2017)
Brand name: Aliqopa
Generic name: copanlisib
Dosage form: Injection
Company: Bayer HealthCare Pharmaceuticals Inc.
Treatment for: Follicular Lymphoma
Aliqopa (copanlisib) is a phosphatidylinositol-3-kinase (PI3K) inhibitor indicated for the treatment of adult patients with relapsed follicular lymphoma (FL).
Development History and FDA Approval Process for Aliqopa
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.